They included 12 studies with 4403 patients with CKD and 239 on dialysis and demonstrated that a mean weighted decline in HbA1c of −0.48 (95% CI −0.61 to −0.35) with DPP-4 inhibitor therapy compared to placebo without any increased risk of hypoglycemia or mortality [126]. The gene discussed is DPP4; the disease is chronic kidney disease.